Biotech Values

[DragonBits]

The point about the AG launch is NOT about irreparable harm.

It is why did AG decide to launch now?

The assumption seems to be that AG has decided MNTA won't be successful at trial. Seemes like a reasonable assumption.

If you could address the real question, why did AG decide to launch at this particular moment in time, then you are addressing the real question bothering the market.

BTW, I believe the market price and short position are valid data points and should be considered as part of the overall analysis of a company's business model. Certainly the market price isn't the only or even the most important data point, but it is right up there near the top. BTW, by price I really mean market valuation.

take care and good luck to all